蛋白酶体抑制剂对胃肠道肿瘤的治疗作用
The therapeutic effects of proteasome inhibitors on gastrointestinal neoplasm
摘要
蛋白酶体是真核细胞中具有多种催化功能的蛋白酶复合物,参与胞内的蛋白水解。最近的研究发现,蛋白酶体与很多肿瘤细胞的发生、发展、药物抵抗及播散有关。蛋白酶体作为一种新的肿瘤治疗的靶分子倍受关注。现综述蛋白酶体抑制剂对于胃肠道肿瘤治疗作用及其相关机制。
出处
《国外医学（肿瘤学分册）》
2004年第10期785-787,共3页
Foreign Medical Sciences (Cancer Section)
参考文献23
-
1Voorhees PM,Dees EC,O′Neil B,et al . The proteasome as a target for cancer therapy. Clin Cancer Res,2003,9(17) :6316- 6325.
-
2Tao GZ, Rott LS, Lowe AW, et al . Hyposmotic stress induces cell growth arrest via proteasome activation and cyclin/cyclin-dependent kinase degradation. J Biol Chem ,2002,277 (22): 19295-19303.
-
3Xu J, Attisano L Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA,2000,97(9) :4820- 4825.
-
4Ogiso Y,Tomida A, Kim HD, et al . Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells. Biochem Biophys Res Commun, 1999,258 (2) :448- 452.
-
5Mitchell BS. The proteasome - an emerging therapeutic target in cancer. N Engl J Med,2003,348(26) :2597-2598.
-
6Adams J, Palombella VJ, Sausville EA, et al . Proteasome inhibitors:a novel class of potent and effective antitumor agents. Cancer Res,1999,59 (11) :2615-2622.
-
7Tilignac T, Temparis S, Combaret L, et al . Chemotherapy inhibits skeletal muscle ubiquitin-proteasome-dependent proteolysis. Cancer Res,2002,62(10) :2771-2777.
-
8Cusack JC Jr,Liu R,Houston M,et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kB Inhibition. Cancer Res,2001,61 (9) :3535-3540.
-
9Golab J, Stoklosa T, Czajka A,et al. Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res,2000,20(3A) :1717-1721.
-
10Desai SD, Li TK, Rodriguez Bauman A, et al . Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res, 2001,61(15) :5926-5932.
-
1亢卉.硼替佐米在恶性血液病中的作用机制[J].中国新药与临床杂志,2006,25(6):459-462. 被引量：9
-
2刘蕾,白砚霞.硼替佐米临床研究进展[J].临床荟萃,2009,24(8):734-736. 被引量：1
-
3陈文明.硼替佐米在多发性骨髓瘤治疗中的应用[J].白血病．淋巴瘤,2008,17(5):325-327. 被引量：13
-
4张卫国,王小虎,王启斌,谢国建,王强,吴清明.泛素蛋白酶体抑制剂MG-132对胃癌细胞增殖和凋亡的影响[J].中国新药与临床杂志,2005,24(5):345-347. 被引量：5
-
5何慧,苏波,杨向东,郭芳,孙文清.蛋白酶体抑制剂对肝癌细胞多药耐药基因表达的影响[J].中国药物与临床,2007,7(7):527-528.
-
6田方,李春海,颜春洪,陈高明.高表达bcl-2卵巢癌细胞系参与药物抵抗和细胞凋亡作用的研究[J].中国肿瘤生物治疗杂志,2000,7(2):106-108.
-
7郭娜,彭芝兰.蛋白酶体抑制剂MG132诱导卵巢癌SKOV3细胞凋亡和自噬的作用机制[J].国际妇产科学杂志,2017,44(1):44-47. 被引量：2
-
8都镇先,高雁艳,刘宝琴,张海燕,王华芹.过氧化物还原酶1对蛋白酶体抑制剂诱导未分化甲状腺癌FRO细胞凋亡作用的研究[J].中华肿瘤防治杂志,2010,17(19):1517-1520. 被引量：2
-
9徐文静,黄纯,李凯.厄洛替尼治疗晚期肺癌10例疗效观察[J].天津医药,2009,37(1):65-66. 被引量：3
-
10王亚伟,欧阳学农,解方为,陈曦,余宗阳.TRAIL与MG132联合诱导肺癌A549细胞凋亡及机制的探讨[J].中华肿瘤防治杂志,2011,18(11):840-843. 被引量：5
